Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
Pak Fah Yeow InternationalHKSE:00239 80 Pretax Margin % is 49.92% as of Dec. 2025, which is 35% above its 10-year median of 36.98. GuruFocus rates HKSE:00239 with a GF Score™ of 80/100 and a GF Value™ of HK$2.17 (Fairly Valued). The stock has 3 warning signs investors should review. Among 961 Drug Manufacturers companies, Pak Fah Yeow International ranks better than 97.4% on this metric.
The historical rank and industry rank for Pak Fah Yeow International's Pretax Margin % or its related term are showing as below:
HKSE:00239'
s Pretax Margin % Range Over the Past 10 Years
Min: -30.92 Med: 36.98 Max: 63.11
Current: 50.24
HKSE:00239's Pretax Margin % is ranked better than 97.4% of 961
companies
in the Drug Manufacturers industry
Industry Median: 7.06
vs HKSE:00239: 50.24
Pak Fah Yeow International (HKSE:00239) Pretax Margin % Explanation
The pretax margin, as know as pretax profit margin, is widely used to measure the operating efficiency of a company before deducting taxes.
The pretax margin is sometimes preferred over the net margin as tax expenditures can make profitability comparisons between companies misleading.
It is a useful tool to compare companies operating in the same sector and less effective when comparing companies from other sectors as each industry generally has different operating expenses and sales patterns.
The long term trend of the pretax margin is a good indicator of the competitiveness and health of the business.
Pak Fah Yeow International Pretax Margin % Related Terms
Pak Fah Yeow International Pretax Margin % Historical Data
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
For the Drug Manufacturers - Specialty & Generic subindustry, Pak Fah Yeow International's Pretax Margin %, along with its competitors' market caps and Pretax Margin % data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Pak Fah Yeow International Pretax Margin % vs Drug Manufacturers Industry
For the Drug Manufacturers industry and Healthcare sector, Pak Fah Yeow International's Pretax Margin % distribution charts can be found below:
* The bar in red indicates where Pak Fah Yeow International's Pretax Margin % falls into.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Pak Fah Yeow International (HKSE:00239) has a Pretax Margin % of 49.92% as of Dec. 2025. Pre-Tax margin is the ratio of total pre-tax income to net sales. View historical data on Pak Fah Yeow International and its competitors. This is 35% above median its historical median of 36.98. According to the industry distribution chart, Pak Fah Yeow International ranks #25 out of 961 companies in the Drug Manufacturers industry, placing it in the top 2.6%.
Is Pak Fah Yeow International's Pretax Margin % too high?
Pak Fah Yeow International's current Pretax Margin % of 49.92% is 35% above median its 10-year median of 36.98. The Drug Manufacturers industry median Pretax Margin % is 7.06. Pak Fah Yeow International's value of 49.92% is 607.1% above this industry median. Based on the distribution chart, Pak Fah Yeow International ranks #25 out of 961 companies in the Drug Manufacturers industry, which is in the top quartile — a strong position relative to peers. Overall, Pak Fah Yeow International has a GF Score™ of 80/100 and is considered Fairly Valued, reflecting its overall financial health beyond just this single metric.
How does Pak Fah Yeow International's Pretax Margin % compare to ZTS?
According to the Drug Manufacturers industry distribution chart, Pak Fah Yeow International ranks #25 out of 961 companies for Pretax Margin %. This places Pak Fah Yeow International in the top 3% of its industry — outperforming the majority of peers. The industry median Pretax Margin % is 7.06. Pak Fah Yeow International's value of 49.92% is 607.1% above this benchmark. While the company's 10-year median is 36.98 vs. the industry median of 7.06, Pak Fah Yeow International has consistently been above the industry average. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Pretax Margin % for a Drug Manufacturers company?
The median Pretax Margin % among Drug Manufacturers companies is 7.06, based on 961 companies in the industry. Companies in the top quartile (top 25%) have a Pretax Margin % significantly above this median, while those in the bottom quartile fall well below. However, Pretax Margin % should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Pak Fah Yeow International's current Pretax Margin % of 49.92% is 607.1% above the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Pretax Margin % mean?
A high Pretax Margin % can signal that a stock is expensive relative to its fundamentals. Pre-Tax margin is the ratio of total pre-tax income to net sales. View historical data on Pak Fah Yeow International and its competitors. For the Drug Manufacturers industry, the median Pretax Margin % is 7.06 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Pak Fah Yeow International's current Pretax Margin % is 49.92%, which is 35% above median its own 10-year median of 36.98. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Pak Fah Yeow International stock overvalued right now?
Based on GuruFocus' analysis, Pak Fah Yeow International (HKSE:00239) is currently considered Fairly Valued. The stock's GF Value™ is HK$2.17, compared to a current price of HK$2.38 — trading 9.4% above its estimated fair value. The current Pretax Margin % is 49.92%, which is 35% above median its 10-year median of 36.98 and 607.1% above the Drug Manufacturers industry median of 7.06. Pak Fah Yeow International's overall GF Score™ is 80/100 with 3 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Pretax Margin % calculated?
Pretax Margin % is calculated from a company's financial statements. For Pak Fah Yeow International (HKSE:00239), the current Pretax Margin % is 49.92% as of Dec. 2025. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is Pak Fah Yeow International (HKSE:00239) Overvalued in 2026?
Based on GuruFocus' analysis, Pak Fah Yeow International stock appears to be overvalued.
The current stock price of HK$2.38 is trading 9.4% above its estimated GF Value™ of HK$2.17.
GuruFocus considers Pak Fah Yeow International to be Fairly Valued.
Key valuation signals for HKSE:00239:
Pretax Margin %: 49.92% (35% above median its 10-year median of 36.98)
GF Value™: HK$2.17 vs. price of HK$2.38 (9.4% above fair value)
Industry Position: 607.1% above the Drug Manufacturers median (#25 of 961)
No single metric tells the full story. See the HKSE:00239 stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
Pak Fah Yeow International Ltd, with its subsidiaries, is engaged in the manufacture and distribution of healthcare products, including Hoe Hin branded products. It also engages in real estate investment and treasury investment businesses. It has three business segments, namely healthcare, property investments, and treasury investments. The Company derives the majority of its revenues from the Healthcare segment.The Groups businesses cover Hong Kong, Macau, other regions in the Peoples Republic of China (the PRC or Chinese Mainland), Southeast Asia, North America and the United Kingdom.
80GF Score
Get the complete analysis for HKSE:00239
Pretax Margin % is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
HKSE:00239 has been successfully added to your 
